Skip to main content
Log in

Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Microarray data suggested that the expression of aldehyde dehydrogenase 1 family member L1 (ALDH1L1) is reduced in hepatocellular carcinoma (HCC). However, the role of ALDH1L1 in HCC carcinogenesis has not been elucidated. In the present study, we investigated the expression of ALDH1L1 in HCC and evaluated its relationship with clinical features and prognosis of HCC patients. Total 112 tumor samples were collected from patients with HCC, who underwent radical hepatectomy. Out of the 112 samples, 16 paired HCC tumorous and corresponding adjacent nontumor tissues were analyzed by real-time quantitative RT-PCR (qRT-PCR) and Western blotting, and the other 96 HCC samples were detected by immunohistochemical method. The qRT-PCR assay showed that the mRNA level of ALDH1L1 was significantly reduced in tumorous tissues compared with the adjacent nontumorous tissues (P = 0.0007), and Western blotting indicated that protein level of ALDH1L1 also notably down-regulated in tumor tissues. Immunohistochemistry detection revealed that decreased ALDH1L1 expression was present in 56.3% (54/96) of HCC patients. Correlation analysis showed that ALDH1L1 expression was significantly correlated with histological differentiation (P = 0.001), HBsAg status (P = 0.024) and serum AFP (P = 0.001). Patients with low expression of ALDH1L1 had poorer prognosis than those with high expression (P = 0.008). Multivariate analysis showed that ALDH1L1 expression was an independent predictor of overall survival (HR, 0.349; 95% CI, 0.157–0.774; P = 0.01). The results in this study, for the first time, reveal that the mRNA and protein expressions of ALDH1L1 are significantly reduced in HCC tissues and its low protein expression is a new and potential prognostic marker for the survival of HCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bruix J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35(3):421–30.

    Article  PubMed  CAS  Google Scholar 

  2. He J, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–34.

    Article  PubMed  CAS  Google Scholar 

  3. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25(27):3771–7.

    Article  PubMed  CAS  Google Scholar 

  4. Feo F, et al. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta. 2006;1765(2):126–47.

    PubMed  CAS  Google Scholar 

  5. Kwon OS, et al. Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. Korean J Hepatol. 2010;16(3):308–14.

    Article  PubMed  Google Scholar 

  6. Chen Ban K, et al. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. J Surg Oncol. 2004;86(3):157–63.

    Article  PubMed  Google Scholar 

  7. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271–85.

    Article  PubMed  CAS  Google Scholar 

  8. Krupenko SA. FDH: an aldehyde dehydrogenase fusion enzyme in folate metabolism. Chem Biol Interact. 2009;178(1–3):84–93.

    Article  PubMed  CAS  Google Scholar 

  9. Krupenko SA, Oleinik NV. 10-formyltetrahydrofolate dehydrogenase one of the major folate enzymes, is down-regulated in tumor tissues and possesses suppressor effects on cancer cells. Cell Growth Differ. 2002;13(5):227–36.

    PubMed  CAS  Google Scholar 

  10. Krebs HA, Hems R, Tyler B. The regulation of folate and methionine metabolism. Biochem J. 1976;158(2):341–53.

    PubMed  CAS  Google Scholar 

  11. Kim DW, et al. Properties of tetrahydropteroylpentaglutamate bound to 10-formyltetrahydrofolate dehydrogenase. Biochemistry. 1996;35(49):15772–83.

    Article  PubMed  CAS  Google Scholar 

  12. Wagner C, et al. 10-Formyltetrahydrofolate dehydrogenase: identification of the natural folate ligand, covalent labeling, and partial tryptic digestion. Arch Biochem Biophys. 1995;316(1):141–7.

    Article  PubMed  CAS  Google Scholar 

  13. Oleinik NV, Krupenko SA. Ectopic expression of 10-formyltetrahydrofolate dehydrogenase in A549 cells induces G1 cell cycle arrest and apoptosis. Mol Cancer Res. 2003;1(8):577–88.

    PubMed  CAS  Google Scholar 

  14. Oleinik NV, Krupenko NI, Krupenko SA. ALDH1L1 inhibits cell motility via dephosphorylation of cofilin by PP1 and PP2A. Oncogene. 2010;29(47):6233–44.

    Article  PubMed  CAS  Google Scholar 

  15. Tackels-Horne D, et al. Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling. Cancer. 2001;92(2):395–405.

    Article  PubMed  CAS  Google Scholar 

  16. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.

    Article  PubMed  CAS  Google Scholar 

  17. Bailey LB, Gregory JF 3rd. Folate metabolism and requirements. J Nutr. 1999;129(4):779–82.

    PubMed  CAS  Google Scholar 

  18. Benkovic SJ. The transformylase enzymes in de novo purine biosynthesis. Trends Biochem Sci. 1984;9:320–2.

    Article  CAS  Google Scholar 

  19. Jhaveri MS, Wagner C, Trepel JB. Impact of extracellular folate levels on global gene expression. Mol Pharmacol. 2001;60(6):1288–95.

    PubMed  CAS  Google Scholar 

  20. Kruman II, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer’s disease. J Neurosci. 2002;22(5):1752–62.

    PubMed  CAS  Google Scholar 

  21. Huang RF, et al. Folate deficiency induces a cell cycle-specific apoptosis in HepG2 cells. J Nutr. 1999;129(1):25–31.

    PubMed  CAS  Google Scholar 

  22. Rodriguez FJ, et al. Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. J Neuropathol Exp Neurol. 2008;67(12):1194–204.

    Article  PubMed  CAS  Google Scholar 

  23. Oleinik NV, et al. Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression. Biochem J. 2005;391(Pt 3):503–11.

    PubMed  CAS  Google Scholar 

  24. Oleinik NV, Krupenko NI, Krupenko SA. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene. 2007;26(51):7222–30.

    Article  PubMed  CAS  Google Scholar 

  25. Ghose S, et al. 10-formyltetrahydrofolate dehydrogenase-induced c-Jun-NH2-kinase pathways diverge at the c-Jun-NH2-kinase substrate level in cells with different p53 status. Mol Cancer Res. 2009;7(1):99–107.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Hui-Yun Wang was supported by a grant (No: 30772491) from the National Natural Science Foundation of China and partially supported by Research Fund of National Key Laboratory of Oncology in South China. The sponsors had no role in the design, methods, subject recruitment, data collection, analysis or preparation of this manuscript.

Conflicts of interest

The authors declare no conflicts of interest in this work.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hui-Yun Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, XQ., He, JR. & Wang, HY. Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma. Med Oncol 29, 1843–1849 (2012). https://doi.org/10.1007/s12032-011-0075-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0075-x

Keywords

Navigation